Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s Cimzia Set To Make A Late Entrance At Psoriasis Party

Executive Summary

UCB has reported positive data from the final Phase III trial of its anti-TNF product Cimzia in plaque psoriasis, paving the way for approval applications later this year, but the product will have to elbow its way into a competitive market already under the shadow of a biosimilar threat.

You may also be interested in...



Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions

Dermira will focus on developing the IL-13 inhibitor in atopic dermatitis, where it sees an opportunity for potential dosing and efficacy benefits. Roche had focused on respiratory disease, with mixed results.

Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera

The latest drug development news and highlights from our US FDA Performance Tracker.

Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting

Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel